Meeting
2022 ASCO Genitourinary Cancers Symposium
An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.
Presenter
Daniel Eidelberg Spratt, MD
University Hospitals Seidman Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
General Session
Session Title
Optimizing Management of Localized Prostate Cancer: Artificial Intelligence, Active Surveillance, and Intervention
Track
Prostate Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 223)
DOI
10.1200/JCO.2022.40.6_suppl.223
Abstract #
223
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Cardiovascular and thromboembolic events associated with intense neoadjuvant androgen deprivation therapy followed by prostatectomy in patients with localized prostate cancer: A meta-analysis of clinical trials.
Speaker: Eduardo Felicio Campos, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).
Speaker: Rana R. McKay, MD
Speaker: Panel Discussion